Clinical Trial

Visual Involvement in Giant Cell Arteritis

Study acronym: Visu-GCA
Recruiting
View on ClinicalTrials.gov →
Summary
This observational study aims to enhance the description of the different ways Giant Cell Arteritis (GCA) affects vision. The latest technology and knowledge are used to improve how we diagnose and predict patient outcomes. GCA is the most frequent vasculitis, an inflammation of vessels, in older adults. It involves large and medium-sized arteries and causes ischemic alterations such as stroke and blindness, through damage of extracranial arteries. The primary objective is to compare the frequency of the various ocular findings between the main alterations of arteritic and non-arteritic aetiology, such as Arteritic Anterior Ischemic Optic Neuropathy (A-AION) Vs. Non-Arteritic Anterior Ischemic Optic Neuropathy (NA-AION) or Central Retinal Artery Occlusion (CRAO) from GCA Vs. from other causes, through a comprehensive clinical and instrumental evaluation.
Trial Details
NCT Number NCT06500728
Lead Sponsor ASST Fatebenefratelli Sacco
Conditions Giant Cell Arteritis, Visual Impairment, Central Retinal Artery Occlusion, Anterior Ischemic Optic Neuropathy, Paracentral Acute Middle Maculopathy, Posterior Ischemic Optic Neuropathy, Retinal Ischemia, Blindness +1 more
Enrollment 762 participants
Start Date 2024-06-27
Primary Completion 2028-06 (estimated)
Study Completion 2030-06 (estimated)
Updated on ClinicalTrials.gov 2024-07-15